Destiny Pharma (GB:DEST) has released an update.
Destiny Pharma, a clinical-stage biotechnology firm, has made its Annual Report for 2023 and Notice of its 2024 AGM available on its website, with printed copies sent to shareholders. The AGM is scheduled for June 12, 2024, and will include a live presentation and Q&A session, with options for remote attendance and question submissions through the Investor Meet Company platform. The company continues to focus on developing innovative treatments aimed at preventing life-threatening infections.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
